Monica Galleano Selected Research

Catechin (Z 7300)

1/2022	( -)-Epicatechin and cardiometabolic risk factors: a focus on potential mechanisms of action.
1/2021	Linking biomarkers of oxidative stress and disease with flavonoid consumption: From experimental models to humans.
7/2020	(-)-Epicatechin protects thoracic aortic perivascular adipose tissue from whitening in high-fat fed mice.
1/2017	LPS-induced renal inflammation is prevented by (-)-epicatechin in rats.
4/2016	Modifications in nitric oxide and superoxide anion metabolism induced by fructose overload in rat heart are prevented by (-)-epicatechin.
1/2016	Dietary (-)-epicatechin mitigates oxidative stress, NO metabolism alterations, and inflammation in renal cortex from fructose-fed rats.
7/2015	(-)-Epicatechin reduces blood pressure increase in high-fructose-fed rats: effects on the determinants of nitric oxide bioavailability.
8/2013	(-)-Epicatechin reduces blood pressure and improves vasorelaxation in spontaneously hypertensive rats by NO-mediated mechanism.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Monica Galleano Research Topics

Disease

7	Hypertension (High Blood Pressure) 01/2022 - 12/2010
4	Body Weight (Weight, Body) 07/2020 - 07/2015
3	Insulin Resistance 01/2022 - 07/2012
3	Inflammation (Inflammations) 01/2021 - 01/2016
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2017 - 07/2012
3	Iron Overload 08/2007 - 07/2002
2	Obesity 01/2022 - 07/2012
2	Chronic Disease (Chronic Diseases) 07/2020 - 01/2016
2	Hypertriglyceridemia 01/2017 - 07/2012
2	Metabolic Diseases (Metabolic Disease) 04/2016 - 01/2016
1	Hyperglycemia 01/2022
1	Dyslipidemias (Dyslipidemia) 01/2022
1	Stroke (Strokes) 01/2021
1	Pre-Eclampsia (Preeclampsia) 01/2021
1	Abdominal Obesity 01/2017
1	Cardiomegaly (Heart Hypertrophy) 04/2016
1	Proteinuria 01/2016
1	Fibrosis (Cirrhosis) 01/2016
1	Chronic Renal Insufficiency 01/2016
1	Hypercholesterolemia 07/2012
1	Endotoxemia 02/2004
1	Hepatomegaly 07/2003

Drug/Important Bio-Agent (IBA)

8	Catechin (Z 7300)IBA 01/2022 - 08/2013
4	FlavonoidsIBA 01/2021 - 07/2012
3	FructoseIBA 01/2017 - 01/2016
3	IronIBA 02/2004 - 07/2002
2	Drinking WaterIBA 04/2016 - 01/2016
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2010 - 02/2004
2	Dextrans (Dextran)FDA Link 07/2003 - 07/2002
1	Polysaccharides (Glycans)IBA 01/2021
1	AntioxidantsIBA 01/2021
1	Galectins (Galectin)IBA 01/2021
1	GlucocorticoidsIBA 01/2017
1	SugarsIBA 01/2017
1	EnzymesIBA 01/2017
1	SolutionsIBA 01/2017
1	Interleukin-6 (Interleukin 6)IBA 01/2016
1	Nitric Oxide Synthase (NO Synthase)IBA 01/2016
1	nephrinIBA 01/2016
1	Superoxides (Superoxide)IBA 07/2015
1	PolyphenolsIBA 12/2010
1	Oxidants (Oxidizing Agents)IBA 12/2010
1	Thiobarbituric Acid Reactive SubstancesIBA 08/2007
1	LipidsIBA 08/2007
1	tert-ButylhydroperoxideIBA 08/2007
1	alpha-Tocopherol FDA Link 07/2003
1	semidehydroascorbic acidIBA 07/2002
1	Indicators and Reagents (Reagents)IBA 07/2002